Noom Med alternatives: what else costs less or bills differently
As of November 20, 2026, Noom Med has no current month-to-month price that can be compared like for like ($299 tirzepatide or $249 semaglutide per 4 weeks after a lower first 4 weeks, billed every 12 weeks ($897 for tirzepatide); a product-page footnote says $279 a month ($837 per 12 weeks) for semaglutide), so the tables below list the programs that do print one.
Released · Last reviewed · how we verify
Tirzepatide: programs around Noom Med
Like-for-like basis: compounded tirzepatide, month to month, all-in, read on each program’s own page on November 20, 2026. Noom Med: $299 per 28-day cycle.
| Program | Month to month, all-in | Basis | Year at that price | Lowest printed rate | Read |
|---|---|---|---|---|---|
| Collective | $85.58 | per month | $1,027 | $85.58 ($69 a month plus $199 a year) | 2026-11-20 |
| Mondae | $126 | per month | $1,512 | $114 (6-month plan, $684) | 2026-11-20 |
| NexLife | $129 | per month | $1,548 | $115 (12-month plan) | 2026-11-20 |
| Eden | $129 | per month | $1,548 | $129 (every month) | 2026-11-20 |
| Yucca Health | $139 | per month | $1,668 | $119 (12-month plan, $1,428 upfront) | 2026-11-20 |
| Fifty 410 | $199 | per 28-day cycle | $2,587 | $149.50 (8-week program at $299, not in all states) | 2026-11-20 |
| Enhance.MD | $329 | per 28-day cycle | $4,277 | $280 (billed every 48 weeks) | 2026-11-20 |
| Found | $339 | per 28-day cycle | $4,407 | $199 (12-month term, per 28-day cycle) | 2026-11-20 |
| Remedy Meds | $399 | per 28-day cycle | $5,187 | $399 (4-week supply; $279 first month only) | 2026-11-20 |
Semaglutide: programs around Noom Med
Like-for-like basis: compounded semaglutide, month to month, all-in, read on each program’s own page on November 20, 2026. Noom Med: $249 per 28-day cycle.
| Program | Month to month, all-in | Basis | Year at that price | Lowest printed rate | Read |
|---|---|---|---|---|---|
| Collective | $75.58 | per month | $907 | $75.58 ($59 a month plus $199 a year) | 2026-11-20 |
| Mondae | $87 | per month | $1,044 | $69 (6-month plan, $414) | 2026-11-20 |
| Yucca Health | $89 | per month | $1,068 | $69 (12-month plan, $828 upfront) | 2026-11-20 |
| Eden | $99 | per month | $1,188 | $99 (every month) | 2026-11-20 |
| NexLife | $109 | per month | $1,308 | $95 (12-month plan) | 2026-11-20 |
| OrderlyMeds | $149 | per month | $1,788 | $74 (2-month new-customer offer, $149) | 2026-11-20 |
| Found | $269 | per 28-day cycle | $3,497 | $149 (12-month term, per 28-day cycle) | 2026-11-20 |
| Henry Meds | $297 | per month | $3,564 | $197 (12 months paid in full, $2,364) | 2026-11-20 |
| Remedy Meds | $299 | per 28-day cycle | $3,887 | $299 (4-week supply; $179 first month only) | 2026-11-20 |
Brand alternatives
FDA-approved brand medication bought direct costs more: Zepbound vials from $299 at 2.5 mg to $449 a month at 7.5–15 mg with refills inside 45 days (LillyDirect, ladder carried from October 15), and Wegovy pens $349 a month (NovoCare, read November 20, 2026). Insurance coverage of a brand drug usually beats any cash price; see the insurance page.
Limitations
Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy. Switching programs means a new prescriber review; ask the new program how it handles your current dose.
Frequently asked
What is the main alternative to Noom Med?
As of November 20, 2026, Noom Med has no current month-to-month price that can be compared like for like ($299 tirzepatide or $249 semaglutide per 4 weeks after a lower first 4 weeks, billed every 12 weeks ($897 for tirzepatide); a product-page footnote says $279 a month ($837 per 12 weeks) for semaglutide), so the tables below list the programs that do print one.
How are alternatives chosen here?
By the same basis for every program: the compounded month-to-month, all-in price at the maintenance dose, read on the program’s own page on November 20, 2026, turned into a year’s cost (12 months, or 13 four-week cycles). Programs that print only a starting-dose or coupon price are listed separately, because their regular cost cannot be confirmed.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Noom Med pricing page (read November 20, 2026)